key: cord-0999248-7s7fgvmd authors: Pérez-García, Felipe; Pérez-Tanoira, Ramón; Iglesias, María Esther; Romanyk, Juan; Arroyo, Teresa; Gómez-Herruz, Peña; González, Rosa; Lapeña García, Sara; Cuadros-González, Juan title: Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2 date: 2020-12-15 journal: J Virol Methods DOI: 10.1016/j.jviromet.2020.114047 sha: e47bbcd2822adbe3f8403c4b772511809c43ee94 doc_id: 999248 cord_uid: 7s7fgvmd OBJECTIVES: Serologic techniques can serve as a complement to diagnose SARS-CoV-2 infection. The objective of our study was to compare the diagnostic performance of six immunoassays to detect antibodies against SARS-CoV-2: three lateral flow immunoassays (LFAs), one ELISA and two chemiluminescence assays (CLIAs). METHODS: We evaluated three LFAs (Alltest, One Step and SeroFlash), one ELISA (Dia.Pro) and two CLIAs (Elecsys and COV2T). To assess the specificity, 60 pre-pandemic sera were used. To evaluate the sensitivity, we used 80 serum samples from patients with positive PCR for SARS-CoV-2. Agreement between techniques was evaluated using the kappa score (k). RESULTS: All immunoassays showed a specificity of 100 % except for SeroFlash (96.7 %). Overall sensitivity was 61.3 %, 73.8 %, 67.5 %, 85.9 %, 88.0 % and 92.0 % for Alltest, One Step, SeroFlash, Dia.Pro, Elecsys and COV2T, respectively. Sensitivity increased throughout the first two weeks from the onset of symptoms, reaching sensitivities over 85 % from 14 days for all LFAs, being One Step the most sensitive (97.6 %), followed by SeroFlash (95.1 %). Dia.Pro, Elecsys and COV2T showed sensitivities over 97 % from 14 days, being 100 % for COV2T. One Step showed the best agreement results among LFAs, showing excellent agreement with Dia.Pro (agreement = 94.2 %, k = 0.884), COV2T (99.1 %, k = 0.981) and Elecsys (97.3 %, k = 0.943). Dia.Pro, COV2T and Elecsys also showed excellent agreement between them. CONCLUSIONS: One Step, Dia.Pro, Elecsys and COV2T obtained the best diagnostic performance results. All these techniques showed a specificity of 100 % and sensitivities over 97 % from 14 days after the onset of symptoms, as well as excellent levels of agreement. Since the beginning of the pandemic due to SARS-CoV-2 in Wuhan in December 2019, the virus has caused as of August 19, 2020, more than 21 million cases and 775,000 deaths worldwide (World Health Organization (2020a) ). An early and accurate diagnosis of SARS-CoV-2 infection is essential for the adequate management of COVID-19 patients and the establishment of infection control measures in order to contain this pandemic. Polymerase chain reaction (PCR) is the reference method for COVID-19 diagnosis but its sensitivity depends on the type of sample (upper or lower respiratory tract) and the time from infection Li et al., 2020; . Serologic tests are useful tools for the diagnosis and management of SARS-CoV-2 infection as a complement of PCR (Krammer and Simon, 2020) . They have also proved their usefulness in epidemiological surveillance studies (Garcia-Basteiro et al., 2020; Pollán et al., 2020) . The vast majority of these tests are based on the detection of IgM and IgG antibodies against SARS-CoV-2 nucleocapsid and spike (Huang et al., 2020) . There are mainly three diagnostic approaches to detect these antibodies: lateral flow immunoassays (LFAs), enzyme-linked immunoassays (ELISAs) and chemiluminescence immunoassays (CLIAs). The aim of our study was to compare the diagnostic performance of six serologic tests for the detection of antibodies against SARS-CoV-2: three LFAs, one ELISA and two CLIAs. The study was performed between 1 st March and 30th April 2020. We included two groups of patients: We evaluated one ELISA which detects IgG and IgM antibodies against nucleocapsid and spike (Dia.Pro COVID-19 [Dia.Pro Diagnostic Bioprobes, Sesto San Giovanni, Italy]). We evaluated two CLIAs for total antibodies (IgM + IgG): Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Mannheim, Germany), which detects antibodies against nucleocapsid and SARS-CoV-2 Total COV2T (Siemens Healthineers, Erlangen, Germany), which detects antibodies against spike (S1). Sensitivity evaluation of CLIA techniques could only be performed with 50 samples due to insufficient sample volume. We considered a positive result for samples in which IgG, IgM or both of them were detected. Specificity and sensitivity with 95 % confidence intervals (95 %CI) were calculated using the results from negative controls and positive PCR patients, respectively. Sensitivity was evaluated globally and also according to the time from the onset of symptoms. Agreement between different techniques was evaluated using the Cohen's kappa score (McHugh, 2012) . Statistical analysis was performed using Stata/IC 13.1 (StataCorp, Texas, USA). Overall serologic results from the different techniques are summarized in Table 1 . All techniques showed a specificity of 100 %, except for SeroFlash LFA, which showed a specificity of 96.7 % due to two samples that were positive for IgM antibodies. Regarding LFAs, the overall sensitivity was 61.3 % for Alltest, 73.8 % for One Step and 67.5 % for SeroFlash. Dia.Pro ELISA showed an overall sensitivity of 85.9 % and CLIAs showed sensitivities of 92.0 % for COV2T and 88.0 % for Elecsys. Regarding LFAs, sensitivity increased within the first two weeks (Table 2) , reaching a sensitivity over 85 % from 14 days from the onset of symptoms for all of them. The most sensitive LFA was One Step (96.7 %), followed by SeroFlash (95.1 %). ELISA and CLIAs showed sensitivities over 97 % from 14 days from the onset of symptoms, being 100 % for COV2T CLIA (Table 2) . Finally, the results for agreement between techniques are summarized in Table 3 . One Step showed the best Our study shows that One Step, Dia.Pro, Elecsys and COV2T achieved the best diagnostic performance results. All these techniques showed a specificity of 100 % and sensitivities over 97 % from 14 days after the onset of symptoms, as well as excellent levels of agreement between them. Serologic tests have emerged as complementary tools to PCR in the diagnosis of SARS-CoV-2, including subclinical presentations (Guo et al., 2020) . Consequently, an increasing number of commercial tests have been developed. Table 4 contains a summary of the studies that have evaluated different commercial immunoassays. Regarding LFAs, NG Biotech (Nicol et al., 2020) , LabOn Time, Avioq and QuickZen (Montesinos et al., 2020) , showed similar results with One Step and SeroFlash in terms of sensitivity and specificity. Regarding ELISAs, Euroimmun has been the most frequently evaluated one, presenting overall sensitivities of 71.1-87.4% (Nicol et al., 2020; Montesinos et al., 2020; Kohmer et al., 2020; Krüttgen et al., 2020) and sensitivities from 14 days after the onset of symptoms ranging from 93.9-100%. However, (Nicol et al., 2020) and (Montesinos et al., 2020) reported lower specificity results (82.0-87.5%) for this ELISA than other authors (Kohmer et al., 2020; Krüttgen et al., 2020) . Regarding CLIAs, Abbott showed sensitivities from 14 days ranging from 84.2-100% (Nicol et al., 2020; Chew et al., 2020) and a high specificity (94.6-100%) (Nicol et al., 2020; Kohmer et al., 2020; Chew et al., 2020) . Finally, in the two studies that evaluated the diagnostic performance of Elecsys, the reported sensitivities and specificities were lower than those obtained in our study (Kohmer et al., 2020; Egger et al., 2020) . In our experience, Dia.Pro, Elecsys and COV2T obtained excellent levels of sensitivity, specificity and agreement. We also showed that those LFAs that use recombinant nucleocapsid and spike antigens (One Step and SeroFlash) could achieve practically the same diagnostic performance results than ELISA and CLIAs. At the beginning of its development, the usefulness of LFAs was questioned due to a lack of official performance validations (Krammer and Simon, 2020; World Health Organization (2020b) ). Nowadays these tests have demonstrated their usefulness and reliability in epidemiological studies (Pollán et al., 2020) , and also in the diagnosis of pneumonia of unknown etiology with negative PCR for SARS-CoV-2 (Pérez-García et al., 2020). Our study presents some limitations. First, it is a retrospective study that has been conducted in a single institution and we did not evaluate sequential samples, which could have been interesting in order to establish the dynamic of these antibodies. Second, sensitivity evaluation of CLIAs was performed only over 50 sera, due to insufficient simple volume. However, the samples that could not be analyzed belonged to the first two weeks after the onset of symptoms. As a consequence, this limitation did not affect the results about sensitivity from 14 days, when the vast majority of patients seroconvert according to different studies (Guo et al., 2020; Montesinos et al., 2020; Pérez-García et al., 2020) . Third, specificity evaluation was done over 60 samples including a wide variety of physical conditions (see Supplementary Table 1 ). It would have been interesting to include more patients with autoimmune diseases or with other viral infections in order to evaluate the specificity of the tests in these subpopulations in which the number of false positives of the serological tests could be much higher than in the general population. Finally, we have analyzed the results of six among all commercialized immunoassays. Consequently, our results should not be extrapolated to other available immunoassays and more comparative prospective multicenter studies and meta-analysis are needed to establish the usefulness of other serologic tests and reinforce our conclusions. In conclusion, One Step LFA, Dia.Pro ELISA and Elecsys and COV2T CLIAs present the best diagnostic performance results. All these techniques showed a specificity of 100 % and sensitivities over 97 % from 14 days after the onset of symptoms, as well as excellent levels of agreement between them. To our knowledge, this study constitutes the first comparative evaluation of these six immunoassays. These findings indicate that these tests could be reliable tools for the diagnosis of COVID-19 and the performance of epidemiological studies. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Since the present study is retrospective, informed consent was not required. The study was conducted according to the ethical requirements established by the Declaration of Helsinki. The Ethics Committee of Hospital Universitario Príncipe de Asturias (Madrid) approved the study (protocol code: Comparativa Sero-COVID). The authors declare that they have no conflicts of interest. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays Serology assays to manage COVID-19 Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG Laboratory diagnosis of coronavirus disease-2019 (COVID-19) Interrater reliability: the kappa statistic Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: a prospective single-center study Laboratory diagnosis of COVID-19: current issues and challenges Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study World Health Organization, Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update Advice on the use of point-of-care immunodiagnostic tests for COVID-19 We thank Rebeca Baileń for her help with the preparation of the manuscript. Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jviromet.2020.114047.